The sale, which is expected to close in the second quarter, will double AngioDynamics’ share of the vascular access market. Vascular access devices are tubes that are surgically implanted into a patient’s large vein and used to deliver antibiotics, nutrition and administer transfusions over a long period of time.
Based in Marlborough, Mass., Navilyst generated $149 million in sales in 2011. Private equity firm Avista Capital Partners purchased Navilyst from Boston Scientific in 2008. AngioDynamics is funding the deal with $97 million of cash on hand and $150 million in financing from JP Morgan, Bank of America and KeyBank National Association, and will issue approximately 9.5 million shares of its common stock in the transaction.
The Ropes & Gray team that advised Navilyst on the deal was led by private equity transactions partner Craig Marcus and included antitrust partner Michael McFalls, benefits partner Renata Ferrari, health care partner Tim McCrystal, real estate partner Peter Alpert, tax partner Leo Arnaboldi, along with associates Allie Alperovich, Doug Brayley, Dierdre Johnson, Danna Kivell, Bryan LaPlant, Amy Olson, Kristin Roshelli, and Sarah Schaffer Raux.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.